The National Institute for Health and Care Excellence (NICE) has issued a draft assessment recommending that Clinuvel’s novel drug, Scenesse (afamelanotide), for preventing phototoxicity in patients with erythropoietic protoporphyria (EPP), should not be available on the National Health Service in England.
Although clinical trial results showed the product “may be effective” and there are no other treatments available for EPP, NICE said it was not clear just how effective the drug was, and that its cost-effectiveness estimates were higher than
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?